Screener
BridgeBio Pharma BBIO Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deferred royalty obligations, net (3) | 871,185 | 855,030 |
| Operating lease liabilities, net of current portion | 14,216 | 3,811 |
| Deferred revenue, net of current portion | 11,776 | 13,080 |
| Other long-term liabilities | 229 | 244 |
| Total liabilities | 3,639,856 | 3,012,606 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible noncontrolling interests | (951) | (570) |
| Stockholders’ deficit: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's other non-current liabilities?
- BridgeBio Pharma (BBIO) reported other non-current liabilities of $229K in Q1 2026.
- How has BridgeBio Pharma's other non-current liabilities changed year-over-year?
- BridgeBio Pharma's other non-current liabilities decreased by 34.9% year-over-year, from $352K to $229K.
- What is the long-term trend for BridgeBio Pharma's other non-current liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's other non-current liabilities has grown at a -51.9% compound annual growth rate (CAGR), from $9.52M to $244K.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about BridgeBio Pharma's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude